Home World News Adding Belzutifan to Pembrolizumab Prolongs DFS After Nephrectomy in Patients with ccRCC... World News Adding Belzutifan to Pembrolizumab Prolongs DFS After Nephrectomy in Patients with ccRCC at Increased Risk for Recurrence By Ogkologos - July 21, 2026 178 0 Facebook Twitter Google+ Pinterest WhatsApp Findings from the LITESPARK-022 study Source RELATED ARTICLESMORE FROM AUTHOR Can ctDNA guide treatment intensification in EGFR mutated non-small cell lung cancer? How to select adjuvant endocrine therapy for postmenopausal women with HR-positive early breast cancer? EMA Recommends Extension of Therapeutic Indications for Abiraterone Acetate MOST POPULAR Can Getting a “Base Tan” Protect You From Sunburn and Skin... March 30, 2023 Development of Secondary T-Cell Cancers After the Use of CAR T-Cells... January 29, 2024 Implanted “Drug Factories” Deliver Cancer Treatment Directly to Tumors April 7, 2022 European Parliament Report on Europe’s Beating Cancer Plan Strengthens Commitment to... September 30, 2026 Load more HOT NEWS EMA Recommends Granting a Marketing Authorisation for the Hybrid Medicine Imatinib This Company Is Turning Scrap Wood Into 10,000+ Guitars For Sick... Encouraging Early Results Seen with Novel MEDI1191 in Advanced Tumours Check Out An All New GreaterGood.Com And Our Renewed Commitment To...
